---
title: "VEO in Pharma: Value, Evidence & Outcomes Explained"
description: Discover how VEO teams combine clinical data, health economics, and real-world outcomes to secure reimbursement and sustain product value throughout the lifecycle.
---

[Glossary ](https://www.tikamobile.com/resources/glossary)

# [VEO in Pharma: Value, Evidence & Outcomes Explained](https://www.tikamobile.com/resources/glossary/veo-in-pharma-value-evidence-outcomes-explained)

 Written by [Eshaan Singh](https://www.tikamobile.com/resources/glossary/author/eshaan-singh) | May 30, 2025 2:38:52 PM

## **Definition**

**VEO** is the discipline within a pharmaceutical or biotech company that fuses clinical efficacy data, health-economic modelling, and real-world outcomes into a single value narrative. Its remit is to demonstrate—quantitatively and credibly—that a therapy not only works but delivers meaningful health benefits at a justifiable cost, satisfying regulators, payers, clinicians, and, ultimately, patients.

### Strategic Role

By uniting [Medical Affairs](https://www.tikamobile.com/resources/glossary/medical-affairs), Health Economics & Outcomes Research (HEOR), and Market Access, VEO turns fragmented data into an integrated evidence package. This package underpins approval submissions, reimbursement negotiations, treatment-guideline inclusion, and post-launch positioning—making VEO a linchpin for timely patient access and sustained commercial success.

## Core Pillars

- **Value** – Articulate how the therapy addresses unmet need, improves quality of life, or reduces total cost of care.
- **Evidence** – Generate and curate late-phase trials, real-world studies, and economic models that withstand HTA and payer scrutiny.
- **Outcomes** – Track and publish real-world performance, feeding back insights that support label expansions, pricing reviews, or updated treatment pathways.

### Lifecycle Contribution

During development, VEO flags evidence gaps early enough to influence endpoint choice and comparator selection. At launch, it supplies robust value dossiers and budget-impact models that speed formulary adoption. In maturity, the function mines electronic health records and registries to show long-term effectiveness, safeguarding market share against new entrants.

## Success Metrics

- **Reimbursement win-rate**—percentage of HTA or payer submissions securing favourable coverage within target timelines.
- **Evidence-gap closure**—proportion of high-priority gaps addressed inside 12 months of identification.
- **Real-world evidence uptake**—frequency with which VEO studies are cited in guidelines, payer reviews, or peer publications.

 

[View full post](https://www.tikamobile.com/resources/glossary/veo-in-pharma-value-evidence-outcomes-explained)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Eshaan Singh"
  },
  "dateModified" : "2025-05-30T14:39:15.772Z",
  "datePublished" : "2025-05-30T14:38:52Z",
  "headline" : "VEO (Value, Evidence, and Outcomes)",
  "image" : {
    "@type" : "ImageObject",
    "height" : 60,
    "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
    "width" : 60
  },
  "mainEntityOfPage" : "https://www.tikamobile.com/resources/glossary/veo-in-pharma-value-evidence-outcomes-explained",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Glossary"
  }
}
```